Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSME9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, represents a firm fixed-price delivery under the company's existing Indefinite Delivery Contract with DLA. This delivery order carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement for specialized pharmaceutical products.
This award is issued under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) prime vendor contract with the Defense Logistics Agency, a $499.999 billion acquisition vehicle established to support recurring medical supply needs of military healthcare facilities worldwide. The PPV-G GEN V represents DLA's comprehensive pharmaceutical supply chain initiative structured around a 30-month base period with three 30-month option periods extending through December 31, 2036. DMS Pharmaceutical Group's established performance across multiple delivery orders for diverse therapeutic categories, including oncology treatments, biologics, immunosuppressants, and specialty pharmaceuticals, demonstrates its critical role as a regional pharmaceutical supplier supporting Department of Defense healthcare operations globally, with no subcontractors identified in the award.
Quick answers
Who was awarded contract SPE2DR26FSME9?
SPE2DR26FSME9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FSME9 worth?
The government has obligated $16,584 on SPE2DR26FSME9.
Is contract SPE2DR26FSME9 an order under another contract?
Yes. SPE2DR26FSME9 is a delivery order under SPE2DR25D9320, an indefinite delivery contract.
Was contract SPE2DR26FSME9 competed?
The extent of competition for SPE2DR26FSME9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award